{"0": {
    "doc": "Data elements",
    "title": "Data elements",
    "content": "| Name | Description | . | Assigned female at birth | Cisgender women and all other persons assigned female at birth (including transgender men and nonbinary persons). | . | Sex assigned at birth = female OR | . | Current breast cancer | Currently diagnosed with invasive or non-invasive breast cancer without having achieved remission. | . | CONDITIONS include `INVASIVE BREAST CANCER` with status active CONDITIONS include `NON-INVASIVE BREAST CANCER` with status active | . | History of bilateral mastectomy | Past history of bilateral mastectomy or unilateral mastecomy on both sides. | . | CONDITIONS include `BILATERAL MASTECTOMY` OR PROCEDURES include `BILATERAL MASTECTOMY` OR (PROCEDURES include `UNILATERAL MASTECTOMY` with laterality left AND PROCEDURES include `UNILATERAL MASTECTOMY` with laterality right) | . | Breast symptoms | Patient reported symptoms concerning for breast disease. | . | REVIEW OF SYMPTOMS OR PATIENT QUESTIONNAIRE include breast-related symptoms, which may inlcude one or more of | . | Breast exam findings | Physical exam findings concerning for breast disease. | . | PHYSICAL EXAM OBSERVATIONS include breast-related symptoms, which may inlcude one or more of | . | Patient eligible for screening | Patient determined to be eligible for screening. | . | See 'Screening eligibility' flow logic | . | Genetic marker or syndrome associated with a high risk of breast cancer | Genetic marker or syndrome associated with a high risk of breast cancer (eg, BRCA1 or BRCA2 genetic variation). | . | . | History of high-dose radiation therapy to the chest | History of high-dose radiation therapy to the chest at a young age. | . | CONDITIONS include `CHEST RADIOTHERAPY` with age of onset &lt;= 30 years | . | Previous breast cancer | Past history of invasive or non-`INVASIVE BREAST CANCER`, with remission. | . | CONDITIONS include `INVASIVE BREAST CANCER` with status inactive, resolved CONDITIONS include `NON-INVASIVE BREAST CANCER` with status inactive, resolved CONDITIONS include `INVASIVE BREAST CANCER, IN REMISSION` with status active CONDITIONS include `NON-INVASIVE BREAST CANCER, IN REMISSION` with status active | . | High-risk breast lesion on previous biopsies | Past pre-malignant or high-risk lesions on breast biopsy at any time. | . | CONDITIONS or DIAGNOSIS CODES include `ATYPICAL HYPERPLASIA`, `ATYPICAL DUCTAL HYPERPLASIA`, `ATYPICAL LOBULAR HYPERPLASIA`, `LOBULAR CARCINOMA IN SITU` DIAGNOSTIC REPORT of breast biopsy pathology includes narrative documentation of pre-malignant or high-risk lesions | . | Patient receiving Hospice Services | Hospice services used by patient during the measurement period. | . | CONDITIONS or ENCOUNTER DIAGNOSES include codes from `HOSPICE INTERVENTION` or `HOSPICE ENCOUNTER` | . | Patient receiving Palliative Care Services | Palliative care services used by patient during the measurement period. | . | CONDITIONS or ENCOUNTER DIAGNOSES include codes from `PALLIATIVE INTERVENTION` or `PALLIATIVE ENCOUNTER` | . | Patient age 66 or older in Institutional Special Needs Plans (SNP) or residing in long-term care facility | Patients age 66 or older in Institutional Special Needs Plans (SNP) or residing in long term care with POS code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period. | . | AGE &gt;= 66 years AND ENCOUNTER DIAGNOSES with POS code 32, 33, 34, 54 or 56 for more than 90 consecutive days | . | Patient with Frailty AND Medication for Dementia | Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period AND a dispensed medication for dementia during the measurement period or the year prior to the measurement period. | . | AGE &gt;= 66 years AND &gt;= 1 ENCOUNTER DIAGNOSES include `CODES TO IDENTIFY FRAILTY` AND &gt;= 1 MEDICATIONS include `DEMENTIA EXCLUSION MEDICATIONS` with dispense | . | Patient with Frailty AND Advanced Illness | Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period AND either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ED or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period. | . | AGE &gt;= 66 years AND &gt;= 1 ENCOUNTER DIAGNOSES include `CODES TO IDENTIFY FRAILTY` AND EITHER &gt;= 1 ENCOUNTER of type acute inpatient where DIAGNOSES include `CODES TO IDENTIFY ADVANCED ILLNESS` OR &gt;= 2 ENCOUNTERS of type outpatient, observation, ED or nonacute inpatient where DIAGNOSES include `CODES TO IDENTIFY ADVANCED ILLNESS` | . | Last mammography | Latest mammography, screening or diagnostic, including film, digital or digital breast tomosynthesis (3D) mammography. Can be determined from presence of radiology report or result documented in a structured form. | . | Latest DIAGNOSTIC REPORT of type `SCREENING MAMMOGRAPHY` OR `DIAGNOSTIC MAMMOGRAPHY` OR Documented result of latest `SCREENING MAMMOGRAPHY` OR `DIAGNOSTIC MAMMOGRAPHY` as BI-RADS score. | . | Date of last mammography | Date of latest mammography. | . | Study date of 'Last mammography' | . | Last mammography result | | . | BI-RADS score of 'Last mammography', as reported in DIAGNOSTIC REPORT or documented in a structured form | . | Pending mammography | Patient has an active mammography order or referral. | . | Most recent ORDER or REFERRAL has exam code `SCREENING MAMMOGRAPHY` AND status is active | . | Pending MRI | Patient has an active MRI order or referral. | . | Most recent ORDER or REFERRAL has exam code `SCREENING MRI` AND status is active | . | Last MRI | Latest MRI, screening or diagnostic. Can be determined from presence of radiology report or result documented in a structured form. | . | Latest DIAGNOSTIC REPORT of type `SCREENING MRI` OR `DIAGNOSTIC MRI` OR Documented result of latest `SCREENING MRI` OR `DIAGNOSTIC MRI` as BI-RADS score. | . | Date of last MRI | Date of latest MRI. | . | Study date of 'Last MRI' | . | Last biopsy | Latest breast biopsy. Can be determined from presence of pathology report or result documented in a structured form. | . | Latest DIAGNOSTIC REPORT of type `BREAST BIOPSY` OR Documented result of latest `BREAST BIOPSY` as diagnostic code. | . | Pending biopsy | Patient has an active biopsy order or referral. | . | Most recent ORDER or REFERRAL where exam code is `BREAST BIOPSY` and status is active | . | BI-RADS 3 consecutive results | Consecutive radiology reports with BI-RADS 3 result in a row, excluding interval BI-RADS 0 results. | . | MOST RECENT DIAGNOSTIC REPORTS of type `SCREENING MRI` OR `DIAGNOSTIC MRI` OR Documented results of latest `SCREENING MRI` OR `DIAGNOSTIC MRI` as BI-RADS score WHERE the results are consecutively BI-RADS 3 or BI-RADS 0. | . | Initial BI-RADS 3 result | First radiology report with BI-RADS 3 result, excluding interval BI-RADS 0 results. | . | First result in 'BI-RADS 3 consecutive results' | . | Date of initial BI-RADS 3 result | Date of initial BI-RADS 3 result. | . | Study date of 'Initial BI-RADS 3 result' | . | Latest BI-RADS 3 result | Latest radiology report with BI-RADS 3 result. | . | Latest result in 'BI-RADS 3 consecutive results' | . | Date of latest BI-RADS 3 result | Date of latest BI-RADS 3 result. | . | Study date of 'Latest BI-RADS 3 result' | . ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/Data%20elements.html",
    
    "relUrl": "/pagecontent/Data%20elements.html"
  },"1": {
    "doc": "Decision to Screen",
    "title": "Decision to Screen",
    "content": "Description . Evaluate criteria to determine age to start and age to stop, screening modality, and screening interval. Clinical Review . Current areas of ambiguity: . | HEDIS measure for breast cancer screening provides clinical criteria for determining whether patient is eligible for quality measure denominator but uses either no age or age 66 years as start date for several indicators of reduced life expectancy. USPSTF cites inadequate evidence on the benefits of screening mammography in women age 75 years or older. Is it reasonable to apply the HEDIS indicators as relative indicators to stop screening? If so, should these apply to age &gt; 74 years or any age range? | HEDIS measure also uses 27 months after last screening mammogram to determine criteria met for numerator. Is this a reasonable cutoff to use as a default for the overdue notification, for which a practice may choose to escalate patient outreach efforts? | . Mid-Level Flow Diagram . Age&#160;&gt;&#160;74? . Continue&#160;routinescreening? . Age&#160;&lt;&#160;40?Recommendation:&#160;biennialscreening&#160;mammogram . Last&#160;mammogramresult&#160;is&#160;BI-RADS&#160;3?Determine&#160;next&#160;due&#160;date . Due&#160;for&#160;screening?Patient&#160;outreachendStart&#160;screening&#160;at&#160;40&#160;years&#160;oldShort-interval&#160;follow-upOrder&#160;screening&#160;mammogramend . yes . no . yes . no . yes . no . yes . no . overdue . due . not due . Semi-Structured Logic Statements . Inclusions . None. Exclusions . | Name | . | Patient is not eligible for screening | . | See 'Screening eligibility' flow logic | . | Patient has exclusions for USPSTF screening pathway | . | See 'High risk exclusions' flow logic | . Events . | Name | . | Age &gt; 74? | . | Patient age &gt; 74 years | . | Continue routine screening? | . | Decision to continue routine screening USPSTF cites inadequate evidence on the benefits of screening mammography in women age 75 years or older. | . | Age &lt; 40? | . | Patient age &lt; 40 years | . | Last mammogram result is BI-RADS 3? | . | BI-RADS score in 'Last mammography result' is 3, probably benign. | . | Due for screening? | . | OVERDUE if next due date &gt; 90 days ago DUE if next due date within 90 days from now OR &lt; 90 days ago Otherwise NOT DUE | . Actions . | Name | . | Start screening at 40 years old | . | Next due date = date patient is 40 years old Screening modality = mammography Screening interval = biennial | . | Recommendation: biennial screening mammogram | . | Screening age = &gt;= 40 Screening modality = mammography Screening interval = biennial | . | Short-interval follow-up | . | See flow 'Follow-up BI-RADS 3' | . | Determine next due date | . | Next due date = 'Date of last mammography' plus 2 years | . | Patient outreach | . | Overdue alert | . | Order screening mammogram | . | ORDER for screening mammography if 'Pending mammography' does not exist | . ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/Decision%20to%20Screen.html",
    
    "relUrl": "/pagecontent/Decision%20to%20Screen.html"
  },"2": {
    "doc": "Follow-up BI-RADS 3",
    "title": "Follow-up BI-RADS 3",
    "content": "Description . For patients who have a screening result of BI-RADS category 3, determine when patient requires short interval screenings. Clinical Review . | Slight differences between NCCN and ACR on intervals and duration of follow-up, recommended modality (either US or diagnostic mammo). There also seems to be variability in practice. As this should be determined by radiologist rather than PCP, goal here is more to assist PCP with awareness of pending/future studies to help with ensuring follow-up rather than providing specific recommendations. Should we attempt to provide guidance to PCP or direct PCP to refer to recommended interval in last imaging report? | What is a reasonable contingency for patients who do not receive short-interval screening at exactly recommended intervals (6 months, 12 month, 24 months)? Modeled a grace period of 3 months. | What is a reasonable contingency for patients who remain categorized BI-RADS 3 after &gt;24 months? They should typically be transitioned to BI-RADS 2 (stable lesion) or BI-RADS 4 or 5 (unstable lesion) after 2-3 years. Should we continue to recommend 1 year interval scan, return to routine screening, or direct PCP to refer to recommended interval in last imaging report? Modeled referral for biopsy here. Also have the option of presenting all 4 possibilities and allowing clinician to choose. | Should MRI be included in interval scans or US and mammography only? | . Mid-Level Flow Diagram . Number&#160;of&#160;BI-RADS&#160;3results? . Interval&#160;of&#160;latestBI-RADS&#160;3&#160;result?Update&#160;next&#160;due&#160;date&#160;6&#160;monthsUpdate&#160;next&#160;due&#160;date&#160;12&#160;monthsUpdate&#160;next&#160;due&#160;date&#160;24&#160;monthsConsider&#160;referral&#160;for&#160;biopsy . 1 . &gt;1 . &lt;3 mos . &lt;9 mos . &lt;21 mos . &gt;24 mos . Semi-Structured Logic Statements . Inclusions . None. Exclusions . None. Events . | Name | . | Number of BI-RADS 3 results? | . | Number of 'BI-RADS 3 consecutive results' | . | Interval of latest BI-RADS 3 result? | . | Interval between 'Date of initial BI-RADS 3 result' and 'Date of latest BI-RADS 3 result' | . Actions . | Name | . | Update next due date 6 months | . | Next due date = 'Date of initial BI-RADS 3 result' plus 6 months | . | Update next due date 12 months | . | Next due date = 'Date of initial BI-RADS 3 result' plus 12 months | . | Update next due date 24 months | . | Next due date = 'Date of initial BI-RADS 3 result' plus 24 months | . | Consider referral for biopsy | . | Consider REFERRAL for biopsy | . ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/Follow-up%20BI-RADS%203.html",
    
    "relUrl": "/pagecontent/Follow-up%20BI-RADS%203.html"
  },"3": {
    "doc": "Follow-up Screening Result",
    "title": "Follow-up Screening Result",
    "content": "Description . Determines next steps, if any, based on result of screening mammogram or biopsy. This may be triggered by a mammography report being received by the system or a mammography BI-RADS result being documented in a structured manner. Clinical Review . Mid-Level Flow Diagram . Latest&#160;screening&#160;testtype? . Actionable&#160;BI-RADS?Update&#160;next&#160;due&#160;date . BI-RADS&#160;score? . Pathology&#160;result?endOrder&#160;interval&#160;screeningReferral&#160;for&#160;biopsyReferral&#160;for&#160;high&#160;risk&#160;evaluationReferral&#160;for&#160;Oncology . mammogram . mri . no . yes . bi-rads 3 . bi-rads 4 or 5 . bi-rads 6 . biopsy . negative . atypical . malignant . Semi-Structured Logic Statements . Inclusions . | Name | . | Primary screening complete | . | See 'Primary Screening Completed' flow logic | . Exclusions . None. Events . | Name | . | Latest screening test type? | . | Most recent resulted test of either 'Last mammography' OR 'Last MRI' OR 'Last biopsy' | . | Actionable BI-RADS? | . | BI-RADS score in 'Last mammography result' is NOT 1 or 2 | . | BI-RADS score? | . | BI-RADS score in 'Last mammography result' | . | Pathology result? | . | Result of pathology for 'Last biopsy' | . Actions . | Name | . | Update next due date | . | Next due date = 'Date of last mammography' plus 2 years | . | Order interval screening | . | ORDER for short interval screening mammography | . | Referral for biopsy | . | REFERRAL for biopsy | . | Referral for high risk evaluation | . | REFERRAL for high risk breast clinic evaluation | . | Referral for Oncology | . | REFERRAL for Oncology evaluation | . ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/Follow-up%20Screening%20Result.html",
    
    "relUrl": "/pagecontent/Follow-up%20Screening%20Result.html"
  },"4": {
    "doc": "High Risk Exclusions",
    "title": "High Risk Exclusions",
    "content": "Description . Clinical characteristics that have been identified in the USPSTF breast screening guidelines as indicative of higher than average risk and therefore excluded from guideline recommendations. Clinical Review . Current areas of ambiguity: . | USPSTF does not specify which genetic markers or syndromes to consider exclusions. Various syndromes exist in other guidelines. NCCN includes a long list of potential markers. What should be the source? Should this be an aggregated list of all syndromes and genetic markers identified in other guidelines, limited list of only those that have an alternative guideline for routine screening, or curated in some other manner? | USPSTF excludes those who have had chest radiation therapy at a ‘young age’. Cutoff used by ACS, ACR and NCCN is &lt;30 years, is this a reasonable age? | . Mid-Level Flow Diagram . Genetic&#160;marker&#160;orsyndrome? . History&#160;of&#160;chestradiation? . Previous&#160;breastcancer? . Previous&#160;atypicalbiopsy?endNo&#160;exclusions&#160;for&#160;USPSTF&#160;screeningpathway . yes . yes . yes . yes . no . no . no . no . Semi-Structured Logic Statements . Inclusions . None. Exclusions . | Name | . | Patient is not eligible for screening | . | See 'Screening eligibility' flow logic | . Events . | Name | . | Genetic marker or syndrome? | . | 'Genetic marker or syndrome associated with a high risk of breast cancer' is TRUE | . | History of chest radiation? | . | 'History of high-dose radiation therapy to the chest' is TRUE | . | Previous breast cancer? | . | 'Previous breast cancer' is TRUE | . | Previous atypical biopsy? | . | 'High-risk breast lesion on previous biopsies' is TRUE | . Actions . | Name | . | No exclusions for USPSTF screening pathway | . | Patient does not meet exclusion crtieria for breast cancer screening guideline | . ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/High%20Risk%20Exclusions.html",
    
    "relUrl": "/pagecontent/High%20Risk%20Exclusions.html"
  },"5": {
    "doc": "High-Level and Mid-Level Flow Diagrams",
    "title": "Mid-level flow diagrams",
    "content": "Breast Cancer Screening Mid-Level Flow DiagramsPrimary screening decisionLogic Path 1Screening EligibleLogic Path 2High Risk ExclusionsLogic Path 3Decision to Screen: Average Risk . Assigned&#160;female&#160;atbirth? . Current&#160;breastcancer? . Past&#160;bilateralmastectomy? . Breast&#160;diseasesymptoms? . Breast&#160;exam&#160;findings?Patient&#160;is&#160;eligible&#160;for&#160;screening . Genetic&#160;marker&#160;orsyndrome? . History&#160;of&#160;chestradiation? . Previous&#160;breastcancer? . Previous&#160;atypicalbiopsy?No&#160;exclusions&#160;for&#160;USPSTF&#160;screeningpathway . Age&#160;&gt;&#160;74? . Continue&#160;routinescreening? . Age&#160;&lt;&#160;40?Recommendation:&#160;biennialscreening&#160;mammogram . Last&#160;mammogramresult&#160;is&#160;BI-RADS&#160;3?Determine&#160;next&#160;due&#160;date . Due&#160;for&#160;screening?Patient&#160;outreachStart&#160;screening&#160;at&#160;40&#160;years&#160;oldShort-interval&#160;follow-upOrder&#160;screening&#160;mammogram . yes . no . no . no . no . no . no . no . no . yes . yes . no . yes . no . yes . no . overdue . due . . Breast Cancer Screening Mid-Level Flow DiagramsCare Delivery and Follow-up Mid-Level Flow DiagramsLogic Path 4Screening Test IncompleteLogic Path 5Follow-up Screening ResultLogic Path 6Follow-up BI-RADS 3 . Latest&#160;screening&#160;testtype? . Actionable&#160;BI-RADS?Update&#160;next&#160;due&#160;date . BI-RADS&#160;score? . Pathology&#160;result?Order&#160;interval&#160;screeningReferral&#160;for&#160;biopsyReferral&#160;for&#160;high&#160;risk&#160;evaluationReferral&#160;for&#160;Oncology . Number&#160;of&#160;BI-RADS&#160;3results? . Interval&#160;of&#160;latestBI-RADS&#160;3&#160;result?Update&#160;next&#160;due&#160;date&#160;6&#160;monthsUpdate&#160;next&#160;due&#160;date&#160;12&#160;monthsUpdate&#160;next&#160;due&#160;date&#160;24&#160;monthsConsider&#160;referral&#160;for&#160;biopsy . mammogram . mri . no . yes . bi-rads 3 . bi-rads 4 or 5 . biopsy . atypical . malignant . 1 . &gt;1 . &lt;3 mos . &lt;9 mos . &lt;21 mos . &gt;24 mos . ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/High-Level%20Flow%20Diagrams.html#mid-level-flow-diagrams",
    
    "relUrl": "/pagecontent/High-Level%20Flow%20Diagrams.html#mid-level-flow-diagrams"
  },"6": {
    "doc": "High-Level and Mid-Level Flow Diagrams",
    "title": "High-Level and Mid-Level Flow Diagrams",
    "content": "The high-level flow diagram identifies several different patient populations based on a patient’s symptoms, past medical history and previous screening results. The flow diagram also points to the corresponding guidelines that outline how that patient should be cared for. The mid-level flow diagram (which is divided across several pages) provides a more detailed view of the logic. It describes how population criteria are defined and decision points that identify relevant guidelines and patient-specific recommendations. Breast Cancer Screening High-Level Flow DiagramPrimary screening decisionCare delivery and follow-upLogic&#160;Path&#160;1Screening&#160;EligibleLogic&#160;Path&#160;2High&#160;Risk&#160;ExclusionsLogic&#160;Path&#160;3Decision&#160;to&#160;Screen:&#160;Average&#160;RiskUS&#160;Preventive&#160;Services&#160;Task&#160;Force.&#160;Screening&#160;for&#160;BreastCancer:&#160;US&#160;Preventive&#160;Services&#160;Task&#160;ForceRecommendation&#160;Statement.&#160;JAMA.&#160;Published&#160;online&#160;April30,&#160;2024.Logic&#160;Path&#160;4Screening&#160;Test&#160;IncompleteLogic&#160;Path&#160;5Follow-up&#160;Screening&#160;ResultLogic&#160;Path&#160;6Follow-up&#160;BI-RADS&#160;3Test resulted . Report . no . yes . no . yes . . BI-RADS 3 . ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/High-Level%20Flow%20Diagrams.html",
    
    "relUrl": "/pagecontent/High-Level%20Flow%20Diagrams.html"
  },"7": {
    "doc": "Screening Eligible",
    "title": "Screening Eligible",
    "content": "Description . Determines whether a patient is eligible for routine breast cancer screening. This includes absolute exclusion criteria for which routine screening is not indicated in all guidelines and pathways. Inidividuals who have certain signs or symptoms concerning for breast cancer or other breast diseases are excluded from routine screening pathways and should have diagnostic testing performed. Clinical Review . Current areas of ambiguity: . | USPSTF does not explicitly state criteria for which patient does not require routine breast cancer screening in their inclusion/exclusion criteria. Are there additional consideration other than those listed below? | ACR does recommend routine screening for transgender women in specific scenarios (have been on hormone therapy and have a higher than average risk of breast cancer as defined by a validated risk model). Otherwise there are no specific recommendations for routine screening of individuals assigned male at birth. | ACR also recommends surveillance mammography in breast cancer survivors who have undergone bilateral mastectomy with autologous reconstruction (vs no reconstruction or nonautologous reconstruction). Should the ACR guidelines be included? | USPSTF does not recommend routine clinical breast exam (CBE), however certain other guidelines do. Here we do not make a recommendation for breast exam but rather make recommendations for next steps if a clinician chooses to do a CBE. | . Mid-Level Flow Diagram . Assigned&#160;female&#160;atbirth? . Current&#160;breastcancer? . Past&#160;bilateralmastectomy? . Breast&#160;diseasesymptoms? . Breast&#160;exam&#160;findings?endPatient&#160;is&#160;eligible&#160;for&#160;screening . yes . no . no . yes . no . yes . yes . no . yes . no . Semi-Structured Logic Statements . Inclusions . None. Exclusions . None. Events . | Name | . | Assigned female at birth? | . | 'Assigned female at birth' is TRUE | . | Current breast cancer? | . | 'Current breast cancer' is TRUE | . | Past bilateral mastectomy? | . | 'History of bilateral mastectomy' is TRUE | . | Breast disease symptoms? | . | 'Breast symptoms' EXIST with date recorded after last recorded screening mammography | . | Breast exam findings? | . | 'Breast exam findings' EXIST with date recorded after last recorded screening mammography | . Actions . | Name | . | Patient is eligible for screening | . | . ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/Screening%20Eligible.html",
    
    "relUrl": "/pagecontent/Screening%20Eligible.html"
  },"8": {
    "doc": "Screening Test Incomplete",
    "title": "Screening Test Incomplete",
    "content": "Description . Identifies patients who have been ordered for screening mammography or for follow-up study for abnormal screening mammography but for whom a study report has not been received or documented as received. Intended for use with either individual patient alerts or for generating asynchronous reports on a cohort/panel of patients in order to target outreach or escalation. Clinical Review . | For BI-RADS 0, assumes most imaging centers will take lead on ordering and arranging recall for futher imaging and PCP will not be placing orders or referral. | Same flow is used for follow-up screening exams in case of BI-RADS 3. Are there any differences in ordering patterns for the short interval scans? | There is potentially another step after follow-up completed if there is a biopsy done and biopsy is malignant, which would require a referral to Oncology. Would it be helpful to have another follow-up that monitors for whether the patient has a completed consult with an Oncologist? In general we would not expect clinicians to be tracking this in a structured manner and they may not digitially import a clinical note from a consulting Oncologist to be used to determine if referral was completed. | . Mid-Level Flow Diagram . Last&#160;mammogramresult&#160;is&#160;BI-RADS&#160;0? . Pendingmammographyorder? . Last&#160;mammogram&#160;isafter&#160;pending&#160;order? . Pending&#160;MRI&#160;order? . Last&#160;MRI&#160;is&#160;afterpending&#160;order? . Pending&#160;biopsyorder? . Last&#160;biopsy&#160;is&#160;afterpending&#160;order?Pending&#160;screening&#160;testNo&#160;pending&#160;screening&#160;test . no . yes . no . yes . yes . no . yes . no . yes . no . no . yes . yes . no . Semi-Structured Logic Statements . Inclusions . | Name | . | Primary screening ordered | . | See 'Decision to Screen' flow logic | . Exclusions . None. Events . | Name | . | Last mammogram result is BI-RADS 0? | . | BI-RADS score in 'Last mammography result' is 0, recall to imaging center | . | Pending mammography order? | . | 'Pending mammography' exists. This may be the initial primary screening order or an interval screening mammogram after a BI-RADS 3 result. | . | Last mammogram is after pending order? | . | 'Date of last mammography' is later than date 'Pending mammography' order or referral was placed | . | Pending MRI order? | . | 'Pending MRI' exists. This may be the initial primary screening order or an interval screening mammogram after a BI-RADS 3 result. | . | Last MRI is after pending order? | . | 'Date of last MRI' is later than date 'Pending MRI' order or referral was placed | . | Pending biopsy order? | . | 'Pending biopsy' exists. | . | Last biopsy is after pending order? | . | Date of 'Last biopsy' is later than date 'Pending biopsy' order or referral was placed | . Actions . None. ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/Screening%20Test%20Incomplete.html",
    
    "relUrl": "/pagecontent/Screening%20Test%20Incomplete.html"
  },"9": {
    "doc": "Single page",
    "title": "Single page",
    "content": " ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/single-page/",
    
    "relUrl": "/single-page/"
  },"10": {
    "doc": "Terminology",
    "title": "Terminology",
    "content": "Terminology defines sets of clinical concepts and convey the specific distinguishing characteristics of the included member concepts. | Clinical Focus - A statement describing the general focus of the set, including a description of the intended constituent concepts. This can include information about clinical relevancy or a statement about the general focus of the set. | Inclusions - A statement that describes what specific concept or code criteria are included and why. | Exclusions - A statement that describes what specific concept or code criteria would normally be included, but are specifically excluded by the authors, including their rationale for exclusions. | . Content . | INVASIVE BREAST CANCERClinical Focus Inclusions Exclusions DCIS | . | NON-INVASIVE BREAST CANCERClinical Focus Inclusions DCISExclusions | . | INVASIVE BREAST CANCER, IN REMISSIONClinical Focus Inclusions Exclusions | . | NON-INVASIVE BREAST CANCER, IN REMISSIONClinical Focus Inclusions Exclusions | . | BILATERAL MASTECTOMYClinical Focus Inclusions Exclusions | . | UNILATERAL MASTECTOMYClinical Focus Inclusions Exclusions | . | CHEST RADIOTHERAPYClinical Focus Inclusions Exclusions | . | ATYPICAL HYPERPLASIAClinical Focus Inclusions Exclusions | . | ATYPICAL DUCTAL HYPERPLASIAClinical Focus Inclusions Exclusions | . | ATYPICAL LOBULAR HYPERPLASIAClinical Focus Inclusions Exclusions | . | LOBULAR CARCINOMA IN SITUClinical Focus Inclusions Exclusions | . | HOSPICE INTERVENTIONClinical Focus Inclusions Exclusions | . | HOSPICE ENCOUNTERClinical Focus Inclusions Exclusions | . | PALLIATIVE INTERVENTIONClinical Focus Inclusions Exclusions | . | PALLIATIVE ENCOUNTERClinical Focus Inclusions Exclusions | . | CODES TO IDENTIFY FRAILTYClinical Focus Inclusions Exclusions | . | DEMENTIA EXCLUSION MEDICATIONSClinical Focus Inclusions Exclusions | . | CODES TO IDENTIFY ADVANCED ILLNESSClinical Focus Inclusions Exclusions | . | SCREENING MAMMOGRAPHYClinical Focus Mammogram intended for routine screening purposesInclusions Film, digital or digital breast tomosynthesis (3D) mammographyExclusions Diagnostic mammography | . | DIAGNOSTIC MAMMOGRAPHYClinical Focus Mammogram intended for diagnostic purposesInclusions Film, digital or digital breast tomosynthesis (3D) mammographyExclusions Screening mammography | . | SCREENING MRIClinical Focus Breast MRI intended for routine screening purposesInclusions Exclusions Diagnostic breast MRI | . ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/Terminology.html",
    
    "relUrl": "/pagecontent/Terminology.html"
  },"11": {
    "doc": "Introduction",
    "title": "Introduction",
    "content": "This document includes Cervical Cancer Screening and Management (CCSM) clinical decision support (CDS) flow diagrams and Level 2 (L2) logic to describe how the evidence-based narrative guidelines are represented as logic statements. It includes: . | High-level and mid-level flow diagrams that visually illustrate portions of the guidelines | A brief description of each portion of the CDS logic | Semi-structured logic statements that list required clinical concepts, inclusion criteria, exclusion criteria, and CDS actions. Of note, these logic statements will continue to be refined. The MITRE team plans to evaluate each logic statement moving forward to identify opportunities where the CDS can be made more efficient and better support a modularized approach. | . ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/introduction.html",
    
    "relUrl": "/pagecontent/introduction.html"
  },"12": {
    "doc": "Logic paths",
    "title": "Logic paths",
    "content": "Semi-structured logic statements are comprised of three “sections” or components, each with a distinct purpose: . | Inclusion - describes target population criteria | Exclusion - removes individuals from the target population based on evidence-based recommendations | CDS Events - describes a decision point or trigger in the logic that leads to a recommendation or action | CDS Actions - describes one or more “products” (e.g., calculations, recommendations) that the logic provides for a patient that meets the inclusion criteria, is not removed by the exclusion criteria, and meets the event criteria | . ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/logic_paths.html",
    
    "relUrl": "/pagecontent/logic_paths.html"
  },"13": {
    "doc": "Pathway",
    "title": "Pathway",
    "content": " ",
    "url": "/CDC-Breast-Cancer-Screening-CDS-L2/pagecontent/pathway.html",
    
    "relUrl": "/pagecontent/pathway.html"
  }
}
